BC
GOSS icon

Bridgefront Capital’s Gossamer Bio GOSS Stock Holding History

Bridgefront Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-159
Closed -$111K – 350
2022
Q1 		$111K Buy
+159
New +$123K 0.14% 230
2021
Q2 		– Sell
-171
Closed -$126K – 715
2021
Q1 		$126K Sell
171
-64
-27% -$51.6K 0.04% 610
2020
Q4 		$182K Buy
+235
New +$185K 0.06% 531

Other funds holding GOSS

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bridgefront Capital's GOSS Position: Q2 2022 in Review

Bridgefront Capital sold out of Gossamer Bio (GOSS) in Q2 2022, closing a stake of 159 shares — an estimated $111K sold.

Bridgefront Capital first reported a position in GOSS in Q4 2020 and held it in 3 quarters. The position peaked at $182K in Q4 2020. 127 funds tracked by Wall St. Rank hold GOSS as of Q2 2022.

  • Bridgefront Capital reported no remaining Gossamer Bio position as of Q2 2022 after selling out during the quarter.
  • Bridgefront Capital sold 159 Gossamer Bio shares in Q2 2022, an estimated $111K.
  • Bridgefront Capital first reported a position in Gossamer Bio in Q4 2020 and held it in 3 quarters.
  • Bridgefront Capital's Gossamer Bio position peaked at $182K in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2022.

Based on Bridgefront Capital's 13F filing for Q2 2022, filed 12 Aug 2022.